New Dental Claim For PREVICOX®
13 years ago
4575 views
Merial are pleased to announce a unique new indication for the highly selective canine NSAID PREVICOX®. The product is now licensed for the relief of pain and inflammation associated with dental surgery in dogs.
An estimated 70% of dogs over 2 years of age may have some degree of periodontal disease1. Extraction of teeth is often necessary for the successful management of this condition and is regarded as a painful procedure. The ability of PREVICOX® to control the pain associated with dental surgery has recently been demonstrated in a double blinded, controlled trial2 in which dogs underwent maxillary canine tooth extraction. The results showed that PREVICOX® treatment significantly reduced pain scores post dental surgery, making it the only NSAID with a specific claim for relief of post-operative dental pain. Results of physical examination and blood testing also confirmed the peri-operative safety profile of PREVICOX®, with no treatment-related adverse effects noted during the trial.
The benefits of PREVICOX®4575 views
Posted
5th September, 2011 10h08
- Licensed for relief of pain and inflammation associated with osteoarthritis and soft tissue, orthopaedic and dental surgery
- The first, and still the most selective, coxib NSAID for dogs
- Rapid absorption means that peak plasma concentrations are reached within 90 minutes
- Safety and efficacy profile confirmed by clinical experience and supported by several published studies
More from
- IVC Evidensia assembles expert team to run new £10m referral hospital
- Home delivery service can increase pet health plan sign-ups by 25%
- Research reveals vital clues to help fight anthelmintic resistance
- Lifetime Achievement Award recognises Harrogate vet’s dedication to improving the health and welfare of rabbits
- Bake sale at Leicestershire vet practice for good cause